Editorial note for clinical investigation

Submitted: 28 November 2020; Accepted: 17 December 2020; Published online: 28 December 2020

Sreejata Chatterjee*
Editorial Office, Clinical Investigation, London, UK

*Author for correspondence: chatterjeesree@hotmail.com

Editorial Note

It feels immense pleasure to share that the Journal of Clinical Investigation (OACLI) issue release frequency has been changed to quarterly (4 issues per year). The first issue of the journal was published in the year 2011 and since then it is growing continuously and publishing a sufficient number of articles in each issue successfully. The main objective of the journal is to publish high-quality, authentic, and up-to-date research going on in the field of Clinical researches. Journal of Clinical Investigation is a hybrid open-access journal, allowing the publication of articles in the subscription as well as in open-access mode.

The Journal of Clinical Investigation is a quarterly journal and publishes articles in English and every article is rigorously peer-reviewed and is published online within 30 days after acceptance. Its Editorial board is composed of renowned foreign researchers from different areas of clinical drug development and methodology. The Editorial Board comprises one Editor-in-Chief and 65 Editors, and each holding higher qualifications in their respective fields.

The journal provides carefully reviewed original research papers, review papers, Clinical Trial Procedures, Clinical Trial Perspectives, Clinical Trial Results, Clinical Trial Studies, Clinical Trial Methodologies, Phase I-IV Clinical Trial Outcomes, Commentaries on Clinical trials, case studies, commentaries, Short Communication, and Letters to the Editors in the areas not limited to Regulations and guidelines on drug development and delivery, legal and Clinical trial legal problems, novel drug testing issues, modern medical techniques, new medical equipment, etc. For the year 2018, OACLI’s impact factor was 2.75*, indexing and abstracting coverage of Publons, Google Scholar, Journal TOCs, Genamics Journal Seek, ReSeck, OCLC WorldCat, and our journal’s PubMed NLM ID- 10155458282. During the calendar year 2019, OACLI received a total of 55 papers, out of which 36 articles (65%) were rejected in the preliminary screening due to plagiarism or being out of the format and peer review process. Around 19 papers were submitted for publication in 2019 after they were approved in the peer-review process. In the 4 issues of Volume 9 published during the year 2019, a total of 19 articles were published (at an average of 5 articles per issue) of which, articles were published from authors all around the world. A total of 78 research scientists from all over the world reviewed the 19 articles published in volume 9. An article’s average publishing lag time was further reduced to 2-3 weeks. The peer-review process takes 21 days to be published after the acceptance of the manuscript and the workflow of the manuscript takes 45 days and a manuscript number will be e-mailed to the corresponding author within 72 hours. During the calendar year 2019, a total of 14 Editors, 27 Reviewers joined the board of OACLI and contributed their invaluable services towards contribution as well as the publication of articles. I take this opportunity to acknowledge the contribution of all Editors during the final editing of articles published and the support rendered by the editorial assistant, and bringing out issues of OACLI in time. I would also like to express my gratitude to all the authors, reviewers, the publisher, the advisory and the editorial board of OACLI, the office bearers for their support in bringing out yet another volume of OACLI and look forward to their unrelenting support to bring out the Volume 11 of OACLI in scheduled time.